CMT Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-61,500
Closed -$4.98M 56
2017
Q3
$4.98M Buy
61,500
+41,900
+214% +$3.2M 0.24% 89
2017
Q2
$1.38M Buy
19,600
+6,700
+52% +$446K 0.09% 119
2017
Q1
$876K Sell
12,900
-75,900
-85% -$5.34M 0.07% 123
2016
Q4
$6.36M Sell
88,800
-74,000
-45% -$5.5M 0.3% 80
2016
Q3
$12.9M Buy
162,800
+20,500
+14% +$1.67M 0.59% 59
2016
Q2
$11.9M Buy
142,300
+7,300
+5% +$648K 0.6% 54
2016
Q1
$12.4M Sell
135,000
-50,200
-27% -$4.53M 0.83% 39
2015
Q4
$18.7M Buy
185,200
+28,200
+18% +$2.93M 0.96% 31
2015
Q3
$15.4M Sell
157,000
-93,500
-37% -$10.4M 0.86% 36
2015
Q2
$29.3M Sell
250,500
-3,300
-1% -$361K 1.8% 15
2015
Q1
$24.9M Buy
253,800
+137,100
+117% +$13.9M 1.81% 14
2014
Q4
$11M Buy
116,700
+68,700
+143% +$7.11M 0.65% 47
2014
Q3
$5.11M Buy
+48,000
New +$4.7M 0.26% 82

Other funds holding GILD

CMT Asset Management's GILD Position: Q4 2017 in Review

CMT Asset Management sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 6,322 shares — an estimated $512K sold.

CMT Asset Management first reported a position in GILD in Q3 2014 and held it in 9 quarters. The position peaked at $8.23M in Q1 2015. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

  • CMT Asset Management reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
  • CMT Asset Management sold 6,322 Gilead Sciences shares in Q4 2017, an estimated $512K.
  • CMT Asset Management first reported a position in Gilead Sciences in Q3 2014 and held it in 9 quarters.
  • CMT Asset Management's Gilead Sciences position peaked at $8.23M in Q1 2015.
  • 1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on CMT Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.